These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 11772908

  • 1. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
    Rossing K, Christensen PK, Jensen BR, Parving HH.
    Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
    [Abstract] [Full Text] [Related]

  • 2. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
    Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH.
    Nephrol Dial Transplant; 2002 Jun; 17(6):1019-24. PubMed ID: 12032191
    [Abstract] [Full Text] [Related]

  • 3. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH.
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [Abstract] [Full Text] [Related]

  • 4. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
    Rossing K, Jacobsen P, Pietraszek L, Parving HH.
    Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
    [Abstract] [Full Text] [Related]

  • 5. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P, Andersen S, Jensen BR, Parving HH.
    J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
    [Abstract] [Full Text] [Related]

  • 6. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.
    Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH.
    Diabetes Care; 2005 Sep; 28(9):2106-12. PubMed ID: 16123474
    [Abstract] [Full Text] [Related]

  • 7. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
    Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH.
    Diabetes; 1997 Mar; 46(3):481-7. PubMed ID: 9032106
    [Abstract] [Full Text] [Related]

  • 8. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
    Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH.
    Diabetes Care; 2003 Jan; 26(1):150-5. PubMed ID: 12502672
    [Abstract] [Full Text] [Related]

  • 9. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [Abstract] [Full Text] [Related]

  • 10. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara I, Takahashi Y, Tanaka A, Koide H.
    Nephron; 2000 Oct; 86(2):247. PubMed ID: 11015024
    [No Abstract] [Full Text] [Related]

  • 11. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
    Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH.
    Diabetes Care; 2000 Dec; 23(12):1725-30. PubMed ID: 11128341
    [Abstract] [Full Text] [Related]

  • 12. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P.
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [Abstract] [Full Text] [Related]

  • 13. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Cachofeiro V, Nieto J, Fernández Vega F, Tato A, Gutierrez E, PRONEDI Study Group.
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [Abstract] [Full Text] [Related]

  • 14. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.
    Christensen PK, Lund S, Parving HH.
    Kidney Int; 2001 Oct; 60(4):1435-42. PubMed ID: 11576357
    [Abstract] [Full Text] [Related]

  • 15. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [Abstract] [Full Text] [Related]

  • 16. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [Abstract] [Full Text] [Related]

  • 17. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P, Reismann J, Pohlmeyer H, Düsing R.
    Dtsch Med Wochenschr; 2001 May 11; 126(19):547-50. PubMed ID: 11402910
    [Abstract] [Full Text] [Related]

  • 18. Discordant responses to two classes of drugs acting on the renin-angiotensin system.
    Sever PS, Chang CL.
    J Renin Angiotensin Aldosterone Syst; 2001 Mar 11; 2(1):25-30. PubMed ID: 11881062
    [Abstract] [Full Text] [Related]

  • 19. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U, Chaisuvannarat V.
    J Med Assoc Thai; 2009 May 11; 92(5):611-7. PubMed ID: 19459520
    [Abstract] [Full Text] [Related]

  • 20. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.
    Nephrol Dial Transplant; 2000 Apr 11; 15(4):487-97. PubMed ID: 10727543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.